Evidence map›Paper›PMID 32982158›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2020

A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome.

Maria Vadalà, Valentina Sunseri Trapani, Giulia Guarrasi, Nicasio Ventura, Massimo Castellucci, Salvatore Cillino

Open access · goldAbstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Maria VadalàBiomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy.ORCID 0000-0002-2726-698X
Valentina Sunseri TrapaniBiomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy.ORCID 0000-0002-3159-0774
Giulia GuarrasiBiomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy.ORCID 0000-0002-0819-5610
Nicasio VenturaBiomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy.ORCID 0000-0001-9842-3930
Massimo CastellucciBiomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy.ORCID 0000-0003-2284-6552
Salvatore CillinoBiomedicine, Neuroscience and Advanced Diagnostic Department, University of Palermo, Palermo, Italy.ORCID 0000-0002-5721-6772
University of Palermo · ITIstituto Euro Mediterraneo di Scienza e Tecnologia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere has been an increasing clinical interest in specific retinal parameters as non-invasive biomarkers of retinal inflammation in diabetic macular edema (DME) that have been shown to have prognostic value, such as hyperreflective retinal fields (HRFs) and subfoveal neuroretinal detachment (SND).

methodsWe conducted a prospective, non-comparative study of treatment-naïve patients with DME to evaluate the efficacy of a Pro Re Nata (PRN) regimen of intravitreal dexamethasone implant 0.7 mg (DexI, Ozurdex™). After administration, patients underwent subsequent injections according to PRN criteria in case of edema relapse, but not earlier than 4 months after the previous treatment. Patients were evaluated at baseline, within 15 days of injection, and every month thereafter. During all visits, best-corrected visual acuity (BCVA) was recorded; central retinal thickness (CRT), type of edema, presence of SND, and presence and number of HRFs were evaluated using swept-source optical coherence tomography (SS-OCT) 3D. Treatment outcome was defined as changes in BCVA, CRT, SND and HRFs at 12 (T12) and 24 (T24) months compared with baseline (T0).

resultsThe study enrolled 24 eyes of 18 patients. The mean duration of follow-up was 18±6.6 months; for all eyes, T12 data were available, while follow-up reached T24 for 12 eyes. BCVA improved significantly and CRT decreased significantly during treatment; the edema was no longer detectable in 13/24 eyes at T12 and 8/12 eyes at T24. No patient presented SND at T12 and T24, and the mean number of HRFs decreased significantly during treatment. Results with CRT and HRFs correlated with BCVA at 12 and 24 months. No significant adverse events were observed.

conclusionIn patients with DME, the intravitreal dexamethasone implant was effective and safe in improving both functional and tomographic parameters. This result is consistent with improvement in biomarkers of inflammation.

Indexed as

dexamethasone implantdiabetic macular edemainflammationintravitreal implantsOzurdexreal-world

Identifiers

PMID32982158
PMCPMC7501979
OpenAlexW3084807906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.